CTS will implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
As previously mentioned in Zika communications distributed on September 21 and October 12, 2018; ord...
The CTS Medical Advisory Board recently agreed upon a revision to our standard testing algorithm thi...
On April 29, 2019, CTS will begin performing Donor-Screen HLA® Class I and II testing on the Str...
On July 6, 2018 the FDA released an industry guidance document for transitioning from individual to ...
We have now added a new section called the "Assay History List" to the "At A Gla...
This is the first update to the original CTS communication distributed on July 6th. As previously co...